Capricor Therapeutics’ Upcoming Financial Results
San Diego-based Capricor Therapeutics (NASDAQ: CAPR), a pioneering biotechnology firm focusing on cell and exosome-based therapeutics for rare diseases, is preparing to share its financial results for the second quarter of 2025. This announcement comes with an array of corporate updates that showcase the advances and future direction of the company.
Conference Call and Webcast Details
On a scheduled date, management will release the financial results after the stock market closes. Following this release, a conference call and webcast will be hosted at 4:30 p.m. ET. This event represents a valuable opportunity for investors and interested parties to engage directly with company executives as they outline the company's strategic focus and operational effectiveness.
Capricor’s Lead Product: Deramiocel
At the heart of Capricor's innovations stands Deramiocel, an allogeneic cardiac-derived cell therapy. Initially developed to combat Duchenne Muscular Dystrophy (DMD), extensive clinical research has demonstrated Deramiocel's potential to preserve heart and skeletal muscle functionality. By leveraging insights from preclinical studies, this groundbreaking therapy is set to significantly impact the treatment landscape for patients suffering from muscular dystrophies.
About the Webcast
The webcast will provide an in-depth review of Capricor's financial performance and strategic updates. Following the live session, a replay will be accessible, catering to those unable to attend the live event. This facet highlights Capricor’s commitment to transparency and stakeholder engagement.
Innovative Therapeutics for Rare Diseases
The realm of rare disease therapy is where Capricor aims to make profound advancements. Utilizing their proprietary StealthX™ technology, they focus on delivering targeted therapies, including vaccines and agents aimed at addressing difficult-to-treat conditions. Their continuing exploration in this area demonstrates a clear commitment to pushing innovation boundaries for the benefit of patients worldwide.
Strategic Partnerships and Licensing
In a recent development, Capricor entered into a partnership with Nippon Shinyaku Co., Ltd. for the commercialization of Deramiocel in the United States and Japan, pending regulatory approval. Such strategic alliances are critical as they provide essential resources necessary for navigating the regulatory landscape and bringing transformative therapies to market.
Getting In Touch
Capricor values open communication with its stakeholders. For media inquiries, Raquel Cona from KCSA Strategic Communications is the point of contact. Furthermore, AJ Bergmann, the company’s Chief Financial Officer, is available for more detailed financial inquiries. Both contacts reflect Capricor's dedication to fostering transparent relationships.
Frequently Asked Questions
What will Capricor Therapeutics announce on August 13, 2025?
Capricor will reveal its financial results for the second quarter of 2025, including updates on its operations and future plans.
How can I access the financial results and updates?
The financial results will be released after market close, followed by a conference call and webcast at 4:30 p.m. ET, with replays available afterward.
What is Deramiocel, and why is it significant?
Deramiocel is Capricor’s lead product candidate designed for treating Duchenne Muscular Dystrophy. It shows promise in preserving muscle function based on extensive research.
Who should I contact for media inquiries about Capricor?
For media inquiries, Raquel Cona from KCSA Strategic Communications is the designated contact person.
What is the role of the StealthX™ technology?
StealthX™ is Capricor’s innovative platform designed for the targeted delivery of therapeutic agents, which will enhance treatment options for rare diseases.
